Engineered regulatory T cells prevent graft-versus-host disease while sparing the graft-versus-leukemia effect after bone marrow transplantation
- 31 October 2010
- journal article
- Published by Elsevier in Leukemia Research
- Vol. 34 (10) , 1374-1382
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Generation of Potent and Stable Human CD4+ T Regulatory Cells by Activation-independent Expression of FOXP3Molecular Therapy, 2008
- Foxp3 occupancy and regulation of key target genes during T-cell stimulationNature, 2007
- Can graft-versus-leukemia reactivity be dissociated from graft-versus-host disease?Frontiers in Bioscience-Landmark, 2007
- Prophylaxis and Treatment of Acute Graft-Versus-Host DiseaseSeminars in Hematology, 2006
- Regulatory T Cell Lineage Specification by the Forkhead Transcription Factor Foxp3Immunity, 2005
- In Vitro–expanded Antigen-specific Regulatory T Cells Suppress Autoimmune DiabetesJournal of Experimental Medicine, 2004
- Control of Regulatory T Cell Development by the Transcription Factor Foxp3Science, 2003
- CD4+CD25+ Immunoregulatory T CellsJournal of Experimental Medicine, 2002
- Generation of a Stable Cell Line Producing High-Titer Self-Inactivating Lentiviral VectorsMolecular Therapy, 2001
- Properties of purified T cell subsets. II. In vivo responses to class I vs. class II H-2 differences.Journal of Experimental Medicine, 1986